All In Biotech

Drug Trial Radar · NCT06651970

Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure

A Multicentre, Open-label, Randomised Phase IV Study to Investigate Acalabrutinib Monotherapy Compared to Investigator's Choice of Treatment in Adults (> 18 Years) With Chronic Lymphocytic Leukaemia and Moderate to Severe Cardiac Impairment

Last checked: Nov 20, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Feb 4, 2025

Primary completion

Sep 30, 2032

Study completion Sep 30, 2032

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Fortrea; CALYX Inc.; eResearch Technology, Inc.; CISCRP
First posted
Oct 22, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This will be a global Phase IV, open-label, randomised study to evaluate the safety and tolerability of acalabrutinib (monotherapy, 100 mg orally \[po\], twice daily \[bd\]) compared to investigator's choice of treatment, in patients with CLL (TN or R/R) and moderate to severe cardiac impairment. Patients with moderate to severe cardiac impairment will include those with moderate to severe cardiac conditions, who may have been excluded from previous acalabrutinib clinical trials and in whom the safety of acalabrutinib was not systematically assessed. The study is planned to take place in approximately 25 centres globally. The study will be conducted in centres that have established close collaboration between the Haematology and Cardiology divisions, preferably with a cardio-oncologist on the team. An IDMC will be responsible for making recommendations for study continuation.

Conditions

  • Chronic Lymphocytic Leukaemia
  • Moderate to Severe Cardiac Impairment

Interventions

  • AcalabrutinibDrug

    Acalabrutinib Monotherapy

  • Investigator's choice of treatmentOther

    control arm treatment type will be defined by the PI prior to randomisation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety endpoints 1: To evaluate the incidence of CV (CardioVascular) adverse events leading to drug discontinuation after acalabrutinib treatment compared to investigators choice of treatment.Time frame: Visits are screening+ 8 visits( every 4 weeks) and then every 16 weeks until termination of the study which would be 4 years from the last subject randomized.
  2. Safety endpoints 2: To evaluate the duration on treatment prior to drug discontinuation due to CV adverse events after acalabrutinib treatment compared to investigators choice of treatment.Time frame: Visits are screening+ 8 visits( every 4 weeks) and then every 16 weeks until termination of the study which would be 4 years from the last subject randomized.
  3. Safety endpoints 3: To evaluate the incidence of life threatening and fatal cardiac events of interest after acalabrutinib treatment compared to investigators choice of treatment.Time frame: Visits are screening+ 8 visits( every 4 weeks) and then every 16 weeks until termination of the study which would be 4 years from the last subject randomized.
  4. Safety endpoints 4: To evaluate the frequency of grade≥3 Adverse events after acalabrutinib treatment compared to investigators choice of treatment.Time frame: Visits are screening+ 8 visits( every 4 weeks) and then every 16 weeks until termination of the study which would be 4 years from the last subject randomized.
  5. Safety endpoints 5: To evaluate the frequency of AESI per Acalabrutinib IB after acalabrutinib treatment compared to investigators choice of treatment.Time frame: Visits are screening+ 8 visits( every 4 weeks) and then every 16 weeks until termination of the study which would be 4 years from the last subject randomized.
  6. Safety endpoints 6: To evaluate the rate of discontinuation due to non-CV adverse events after acalabrutinib treatment compared to investigators choice of treatment.Time frame: Visits are screening+ 8 visits( every 4 weeks) and then every 16 weeks until termination of the study which would be 4 years from the last subject randomized.
  7. Safety endpoints 7: To evaluate the rate of any serious adverse event after acalabrutinib treatment compared to investigators choice of treatment.Time frame: Visits are screening+ 8 visits( every 4 weeks) and then every 16 weeks until termination of the study which would be 4 years from the last subject randomized.

Locations

23 sites in 6 countries. Site status is shown where the registry gives one.

  • Research Site

    Charlotte, North Carolina · Withdrawn

  • Research Site

    Columbus, Ohio · Recruiting

  • Research Site

    Philadelphia, Pennsylvania · Recruiting

  • Research Site

    Brno, Czechia · Recruiting

  • Research Site

    Hradec Králové, Czechia · Withdrawn

  • Research Site

    Prague, Czechia · Recruiting

  • Research Site

    Cagliari, Italy · Recruiting

  • Research Site

    Florence, Italy · Recruiting

  • Research Site

    Milan, Italy · Recruiting

  • Research Site

    Milan, Italy · Recruiting

  • Research Site

    Pavia, Italy · Recruiting

  • Research Site

    Perugia, Italy · Recruiting

  • Research Site

    Krakow, Poland · Recruiting

  • Research Site

    Poznan, Poland · Recruiting

  • Research Site

    Barcelona, Spain · Recruiting

  • Research Site

    Madrid, Spain · Recruiting

  • Research Site

    Seville, Spain · Recruiting

  • Research Site

    Bournemouth, United Kingdom · Withdrawn

  • Research Site

    Oxford, United Kingdom · Recruiting

  • Research Site

    Plymouth, United Kingdom · Recruiting

  • Research Site

    Romford, United Kingdom · Withdrawn

  • Research Site

    Stockton, United Kingdom · Withdrawn

  • Research Site

    Sutton Coldfield, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.